Market Research Logo

Kidney Transplantation - Pipeline Review, H1 2016

Introduction
Global Markets Direct Report Coverage
Kidney Transplantation Overview
Therapeutics Development
Pipeline Products for Kidney Transplantation – Overview
Pipeline Products for Kidney Transplantation – Comparative Analysis
Kidney Transplantation – Therapeutics under Development by Companies
Kidney Transplantation – Therapeutics under Investigation by Universities/Institutes
Kidney Transplantation – Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Kidney Transplantation – Products under Development by Companies
Kidney Transplantation – Products under Investigation by Universities/Institutes
Kidney Transplantation – Companies Involved in Therapeutics Development
Alexion Pharmaceuticals, Inc.
Amgen Inc.
Amyndas Pharmaceuticals LLC
Angion Biomedica Corp.
Astellas Pharma Inc.
Bio-inRen
Catalyst Biosciences, Inc.
Corline Biomedical AB
CSL Limited
Digna Biotech, S.L.
Dompe Farmaceutici S.p.A.
Effimune SAS
FibroGen, Inc.
GlaxoSmithKline Plc
Grifols, S.A.
Hansa Medical AB
Kyowa Hakko Kirin Co., Ltd.
Mabtech Limited
Noorik Biopharmaceuticals AG
Novartis AG
Opsona Therapeutics Limited
Pharming Group N.V.
Prolong Pharmaceuticals, LLC
Quark Pharmaceuticals, Inc.
Shire Plc
t-cell Europe GmbH
Tiziana Life Sciences Plc
Zyrnat Biotherapeutics SL
Kidney Transplantation – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
albumin (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AMY-101 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AS-2521780 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
basiliximab biobetter - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BB-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
belimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bleselumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BRN-1889 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (human) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C1 esterase inhibitor (recombinant) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cardiotrophin-1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
carfilzomib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CB-2782 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for Kidney Transplant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cellular Immunotherapy for Multiple Sclerosis and Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CFZ-533 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eculizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
EFFI-7H - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FCR-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FG-4497 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
foralumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FR-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FX-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody to Inhibit CD47 for Cardiovascular Disease, Kidney Transplantation and Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MRX-109 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-003 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPN-305 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
QPI-1002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Renaparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
reparixin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sanguinate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TNT-009 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZY-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Kidney Transplantation – Recent Pipeline Updates
Kidney Transplantation - Dormant Projects
Kidney Transplantation – Discontinued Products
Kidney Transplantation – Product Development Milestones
Featured News & Press Releases
Apr 04, 2016: FDA clears Hansa Medical’s IND application for IdeS in kidney transplantation
Mar 11, 2016: Study results presented in New England Journal of Medicine strengthen Hansa Medical belief in the potential of IdeS
Dec 07, 2015: True North Therapeutics Presents Data in Patients with Cold Agglutinin Disease Supporting Patient Profiles for TNT009 Phase 1b Study
Nov 13, 2015: Data shows that one dose of IdeS has favorable effect and completely removes HLA-antibodies
Nov 10, 2015: Data showing that IdeS can silence memory B-cells published in Journal of Immunology
Oct 30, 2015: Licensee's drug to commence Phase 2 and Phase 3 trials
Oct 13, 2015: Shire's CINRYZE (C1 esterase inhibitor [human]) Receives FDA Fast Track Designation for Investigation in the Treatment of Antibody Mediated Rejection in Patients Receiving Kidney Transplants
Sep 15, 2015: Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015
Sep 14, 2015: Hansa Medical receives FDA Orphan Drug Designation for IdeS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Kidney Transplantation, H1 2016
Number of Products under Development for Kidney Transplantation – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Comparative Analysis by Unknown Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2016
Kidney Transplantation – Pipeline by Alexion Pharmaceuticals, Inc., H1 2016
Kidney Transplantation – Pipeline by Amgen Inc., H1 2016
Kidney Transplantation – Pipeline by Amyndas Pharmaceuticals LLC, H1 2016
Kidney Transplantation – Pipeline by Angion Biomedica Corp., H1 2016
Kidney Transplantation – Pipeline by Astellas Pharma Inc., H1 2016
Kidney Transplantation – Pipeline by Bio-inRen, H1 2016
Kidney Transplantation – Pipeline by Catalyst Biosciences, Inc., H1 2016
Kidney Transplantation – Pipeline by Corline Biomedical AB, H1 2016
Kidney Transplantation – Pipeline by CSL Limited, H1 2016
Kidney Transplantation – Pipeline by Digna Biotech, S.L., H1 2016
Kidney Transplantation – Pipeline by Dompe Farmaceutici S.p.A., H1 2016
Kidney Transplantation – Pipeline by Effimune SAS, H1 2016
Kidney Transplantation – Pipeline by FibroGen, Inc., H1 2016
Kidney Transplantation – Pipeline by GlaxoSmithKline Plc, H1 2016
Kidney Transplantation – Pipeline by Grifols, S.A., H1 2016
Kidney Transplantation – Pipeline by Hansa Medical AB, H1 2016
Kidney Transplantation – Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016
Kidney Transplantation – Pipeline by Mabtech Limited, H1 2016
Kidney Transplantation – Pipeline by Noorik Biopharmaceuticals AG, H1 2016
Kidney Transplantation – Pipeline by Novartis AG, H1 2016
Kidney Transplantation – Pipeline by Opsona Therapeutics Limited, H1 2016
Kidney Transplantation – Pipeline by Pharming Group N.V., H1 2016
Kidney Transplantation – Pipeline by Prolong Pharmaceuticals, LLC, H1 2016
Kidney Transplantation – Pipeline by Quark Pharmaceuticals, Inc., H1 2016
Kidney Transplantation – Pipeline by Shire Plc, H1 2016
Kidney Transplantation – Pipeline by t-cell Europe GmbH, H1 2016
Kidney Transplantation – Pipeline by Tiziana Life Sciences Plc, H1 2016
Kidney Transplantation – Pipeline by Zyrnat Biotherapeutics SL, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Kidney Transplantation Therapeutics – Recent Pipeline Updates, H1 2016
Kidney Transplantation – Dormant Projects, H1 2016
Kidney Transplantation – Dormant Projects (Contd..1), H1 2016
Kidney Transplantation – Dormant Projects (Contd..2), H1 2016
Kidney Transplantation – Discontinued Products, H1 2016
List of Figures
Number of Products under Development for Kidney Transplantation, H1 2016
Number of Products under Development for Kidney Transplantation – Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Top 10 Targets, H1 2016
Number of Products by Stage and Top 10 Targets, H1 2016
Number of Products by Top 10 Mechanism of Actions, H1 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Top 10 Molecule Types, H1 2016
Number of Products by Stage and Top 10 Molecule Types, H1 2016

Kidney Transplantation - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Kidney Transplantation - Pipeline Review, H1 2016’, provides an overview of the Kidney Transplantation pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Transplantation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Transplantation and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Kidney Transplantation
  • The report reviews pipeline therapeutics for Kidney Transplantation by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Kidney Transplantation therapeutics and enlists all their major and minor projects
  • The report assesses Kidney Transplantation therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Kidney Transplantation
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Kidney Transplantation
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Kidney Transplantation pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;